BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved kidney failure drug to market as a potential treatment for liver disease. | BioVie is eyeing a ...

Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy. | Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its ...

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor ...

For all of the benefit that radiopharmaceuticals offer, these treatments currently address a limited number of cancer targets. Aktis Oncology has technology that could broaden the reach of this type ...

Biotech IPOs fell to a decade low in 2025 Investors expect more listings amid easing rate pressure Policy clarity under Trump has reduced worst-case fears Late-stage drug pipelines drawing renewed ...

Chungui International BioTech Group has filed for an initial public offering. The consumer goods company said it will sell 3 million units at $5 apiece, according to a filing with the Securities and ...

The biotech industry’s challenging years might finally be giving way to more optimism as a new funding wave takes shape.

The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.

The life sciences industry is poised for an upswing in initial public offering (IPO) activity in 2026, supported by a large IPO backlog, the strong performance of biotech market indices, and positive ...

MapLight Therapeutics Inc.’s (NASDAQ: MPLT) initial public offering tempted some huge insider buying. Kinder Morgan Inc. (NYSE: KMI), MSC Industrial Direct Co. Inc. (NYSE: MSM), and others also saw ...

Biotech is dominating the (very) early 2026 deals market, whether that be startup fundings, IPOs, or mergers. Why it matters: This is a reversal of the usual order, in which biotech plays distant ...